放疗期间同步顺铂输注治疗转移性黑色素瘤

Mark A. Rosenthal , Colin A. Bull , Alan S. Coates , Graham Stevens , W.H. McCarthy , H. Mameghan , Richard F. Kefford
{"title":"放疗期间同步顺铂输注治疗转移性黑色素瘤","authors":"Mark A. Rosenthal ,&nbsp;Colin A. Bull ,&nbsp;Alan S. Coates ,&nbsp;Graham Stevens ,&nbsp;W.H. McCarthy ,&nbsp;H. Mameghan ,&nbsp;Richard F. Kefford","doi":"10.1016/0277-5379(91)90416-B","DOIUrl":null,"url":null,"abstract":"<div><p>In two pilot studies, 55 patients with symptomatic metastases from malignant melanoma were treated with irradiation and concurrent cisplatin. In the first group, cisplatin was given as a continuous intravenous infusion of 20 mg/m<sup>2</sup> per day on days 1–5 and 22–26, with irradiation on days 2, 5, 9, 16, 23 and 26. The second group received 20 mg cisplatin over 24 h commencing 1 h before each fraction of irradiation on days 1, 4, 8, 11, 15 and 18. The first series of 28 patients had 30 lesions treated. Nine (30%) of these lesions responded completely and 10 (33%) achieved partial response for an overall response rate of 63% (95% confidence interval 44–80%). Survival was not evaluated in this group. The second group was comprised of 27 patients, with one irradiated lesion each. 1 patient achieved a complete response and 13 (48%) a partial response for an overall response rate of 52% (32–71%). Median survival was 21 weeks (16–31 weeks). Treatment was well tolerated with nausea and vomiting being the most common toxicity. Synchronous cisplatin infusion with radiotherapy achieves high response rates in metastatic melanoma. Whether it is superior to radiotherapy alone will require evaluation in a randomised trial.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90416-B","citationCount":"8","resultStr":"{\"title\":\"Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma\",\"authors\":\"Mark A. Rosenthal ,&nbsp;Colin A. Bull ,&nbsp;Alan S. Coates ,&nbsp;Graham Stevens ,&nbsp;W.H. McCarthy ,&nbsp;H. Mameghan ,&nbsp;Richard F. Kefford\",\"doi\":\"10.1016/0277-5379(91)90416-B\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>In two pilot studies, 55 patients with symptomatic metastases from malignant melanoma were treated with irradiation and concurrent cisplatin. In the first group, cisplatin was given as a continuous intravenous infusion of 20 mg/m<sup>2</sup> per day on days 1–5 and 22–26, with irradiation on days 2, 5, 9, 16, 23 and 26. The second group received 20 mg cisplatin over 24 h commencing 1 h before each fraction of irradiation on days 1, 4, 8, 11, 15 and 18. The first series of 28 patients had 30 lesions treated. Nine (30%) of these lesions responded completely and 10 (33%) achieved partial response for an overall response rate of 63% (95% confidence interval 44–80%). Survival was not evaluated in this group. The second group was comprised of 27 patients, with one irradiated lesion each. 1 patient achieved a complete response and 13 (48%) a partial response for an overall response rate of 52% (32–71%). Median survival was 21 weeks (16–31 weeks). Treatment was well tolerated with nausea and vomiting being the most common toxicity. Synchronous cisplatin infusion with radiotherapy achieves high response rates in metastatic melanoma. Whether it is superior to radiotherapy alone will require evaluation in a randomised trial.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90416-B\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/027753799190416B\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190416B","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

摘要

在两项初步研究中,55名有症状的恶性黑色素瘤转移患者接受了放射治疗和顺铂治疗。第一组患者在第1-5天、22-26天连续静脉输注顺铂20 mg/m2 /天,第2、5、9、16、23和26天进行照射。第二组在第1、4、8、11、15和18天的每个部分照射前1小时开始24小时内接受顺铂20mg。第一组28例患者治疗了30个病灶。其中9个(30%)病灶完全缓解,10个(33%)病灶部分缓解,总缓解率为63%(95%置信区间44-80%)。该组患者的生存期未进行评估。第二组由27例患者组成,每个患者有一个辐照病变。1例患者达到完全缓解,13例(48%)达到部分缓解,总缓解率为52%(32-71%)。中位生存期为21周(16-31周)。治疗耐受性良好,恶心和呕吐是最常见的毒性。顺铂同步输注放疗治疗转移性黑色素瘤有效率高。是否优于单独放疗需要在随机试验中评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma

In two pilot studies, 55 patients with symptomatic metastases from malignant melanoma were treated with irradiation and concurrent cisplatin. In the first group, cisplatin was given as a continuous intravenous infusion of 20 mg/m2 per day on days 1–5 and 22–26, with irradiation on days 2, 5, 9, 16, 23 and 26. The second group received 20 mg cisplatin over 24 h commencing 1 h before each fraction of irradiation on days 1, 4, 8, 11, 15 and 18. The first series of 28 patients had 30 lesions treated. Nine (30%) of these lesions responded completely and 10 (33%) achieved partial response for an overall response rate of 63% (95% confidence interval 44–80%). Survival was not evaluated in this group. The second group was comprised of 27 patients, with one irradiated lesion each. 1 patient achieved a complete response and 13 (48%) a partial response for an overall response rate of 52% (32–71%). Median survival was 21 weeks (16–31 weeks). Treatment was well tolerated with nausea and vomiting being the most common toxicity. Synchronous cisplatin infusion with radiotherapy achieves high response rates in metastatic melanoma. Whether it is superior to radiotherapy alone will require evaluation in a randomised trial.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信